A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands
- 1 May 2011
- journal article
- research article
- Published by Elsevier BV in Biochemical Pharmacology
- Vol. 81 (9), 1145-1151
- https://doi.org/10.1016/j.bcp.2011.02.009
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438), a Novel and Potent Potassium-Competitive Acid Blocker for the Treatment of Acid-Related DiseasesJournal of Pharmacology and Experimental Therapeutics, 2010
- The gastric HK-ATPase: structure, function, and inhibitionPflügers Archiv - European Journal of Physiology, 2008
- Nocturnal acid breakthrough: Clinical significance and managementJournal of Gastroenterology and Hepatology, 2006
- Gastroesophageal reflux diseaseCurrent Opinion in Pharmacology, 2005
- CYP2C19 Polymorphism and Proton Pump InhibitorsBasic & Clinical Pharmacology & Toxicology, 2004
- Role of ADP-ribosylation Factor 6 (ARF6) in Gastric Acid SecretionJournal of Biological Chemistry, 2003
- Novel therapeutic strategies in acid-related disordersExpert Opinion on Therapeutic Patents, 2003
- Topical ReviewThe Journal of Physiology, 2001
- Gastric acidity and acid breakthrough with twice‐daily omeprazole or lansoprazoleAlimentary Pharmacology & Therapeutics, 2000
- Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazoleBritish Journal of Clinical Pharmacology, 1998